Accuri Completes $13M Series C Round to Ramp Up Marketing for Low-Cost Cytometer | GenomeWeb
Accuri Cytometers this week announced the completion of a $13 million Series C financing round led by new investors Fidelity Biosciences and Flagship Ventures. Current investors, including Baird Venture Partners and Arboretum Ventures, also participated in the round.
 
An Accuri official said that the company will use the money to expand commercialization activities for its C6 flow cytometer system.
 

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.